Pages that link to "Q57270368"
Jump to navigation
Jump to search
The following pages link to Weekly oral prednisolone improves survival and strength in malemdx mice (Q57270368):
Displaying 26 items.
- Destabilization of the dystrophin-glycoprotein complex without functional deficits in alpha-dystrobrevin null muscle (Q28473016) (← links)
- Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy (Q28474542) (← links)
- Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse (Q28482090) (← links)
- Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function (Q30576097) (← links)
- Modified forelimb grip strength test detects aging-associated physiological decline in skeletal muscle function in male mice (Q30837885) (← links)
- Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy (Q33649312) (← links)
- Effects of prednisolone on skeletal muscle contractility in mdx mice (Q33887318) (← links)
- Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures (Q33975979) (← links)
- PKC theta ablation improves healing in a mouse model of muscular dystrophy (Q34163572) (← links)
- Prednisolone treatment and restricted physical activity further compromise bone of mdx mice. (Q36006306) (← links)
- Age-related T2 changes in hindlimb muscles of mdx mice (Q36145433) (← links)
- Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program (Q36371465) (← links)
- Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy (Q36841572) (← links)
- Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy (Q36957496) (← links)
- Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle. (Q37063632) (← links)
- Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention (Q37583167) (← links)
- Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb Girdle Muscular Dystrophy (Q38617041) (← links)
- Motor performance of young dystrophic mdx mice treated with long-circulating prednisolone liposomes (Q39663447) (← links)
- Co-administration of deflazacort and doxycycline: a potential pharmacotherapy for Duchenne muscular dystrophy (Q40955126) (← links)
- Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy. (Q42234763) (← links)
- Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy (Q42587467) (← links)
- Probing the Pathogenesis of Duchenne Muscular Dystrophy Using Mouse Models. (Q45967109) (← links)
- Molecular hydrogen alleviates motor deficits and muscle degeneration in mdx mice. (Q53180281) (← links)
- Therapeutic effects of exon skipping and losartan on skeletal muscle of mdx mice. (Q53263857) (← links)
- Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor Safinamide Ameliorates the Pathological Phenotype in Mice and in Myogenic Cultures From DMD Patients (Q58781307) (← links)
- Glycine administration attenuates progression of dystrophic pathology in prednisolone-treated dystrophin/utrophin null mice (Q90045029) (← links)